Horizon Discovery Sign Multi-Year Technology Access Agreement with Genentech
News Dec 24, 2009
Through an additional agreement, Horizon Discovery has provided open access to its 150+ strong X-MAN™ cell-line library to Genentech, Inc., a wholly-owned member of the Roche Group, for a period of up to three years. Genentech will utilize the in-licensed cell-line panels in its oncology research programs. The relationship builds on the previous business agreements between the companies.
X-MAN ‘Mutant And Normal’ cell-lines provide researchers with a consistent source of human cell-types that harbor a specific cancer causing gene (or genes), plus a matched reference normal cell as a control; enabling the rational development of novel drugs or treatments that more effectively target specific patient populations.
Dr Paul Morrill, Business Development Director of Horizon says “Genentech have been a model early-adopter and pivotal to Horizon validating its GENESIS™ and X-MAN technology in an industrial setting. The relationship has yielded some exciting findings which are being translated into publications that will help others striving to develop targeted cancer agents. We believe the new open-access deal with Genentech will further enable Horizon to continue to supply first-in-class, in-vitro models of human cancer for Rx and Dx applications.”
Through its agreements, Genentech pays Horizon undisclosed up-front, milestone and renewal fees.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE